- Meatech 3D Ltd (NASDAQ:MITC) reported a loss of $(6.82) million in the first half of FY21, versus $(12.96) million last year.
- Research and development expenses increased to $2.1 million. The operating loss narrowed to $(6.73) million.
- The company held $30.6 million in cash and equivalents as of June 30, 2021.
- Cash flow used in operating activities totaled $5 million in 1H.
- “During the first half of 2021, we expanded our bovine and avian cell product lines, and initiated research and development activities for cultured porcine cell technologies,” said CEO Sharon Fima.
- In August 2021, ​​​​​​​Meatech 3D completed the process to voluntarily delist its ordinary shares from the Tel Aviv Stock Exchange.
- Price Action: MITC shares are trading lower by 2.94% at $6.4159 on the last check Monday.
Related Posts
Tilray’s Fiscal 2022 Revenue Grows 22% YoY, Here Are The Details
Tilray Brands, Inc. (NASDAQ: TLRY) (TSX:TLRY) net revenue grew 8% to $153.3 million during the fourth quarter 2022, from $142.2 million in the prior year quarter.
Citigroup Assumes CarGurus at Neutral, Announces Price Target of $14
Citigroup analyst Ronald Josey assumes CarGurus (NASDAQ:CARG) with a Neutral rating and announces Price Target of $14.
TFF Pharmaceuticals Q1 EPS $(0.33) Beats $(0.38) Estimate, Sales $67.44K Up From $24.32K YoY
TFF Pharmaceuticals (NASDAQ:TFFP) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.38) by 13.16 percent. This is unchanged from the same period last year. The company